BioSpace News Archive

Kata® Clinical app supports Phase Ila proof-of-concept study investigating sterna biologicals’ lead compound SB010 in moderate to severe asthma patients.

Theralase® Technologies Inc. has released the Company’s unaudited 3Q2021 condensed interim consolidated Financial Statements, which provides financial information on the previous fiscal quarter and the quarterly Newsletter which provides an interim clinical data analysis on the Phase II Non-Muscle Invasive Bladder Cancer clinical study.

MedX Health Corp. announced its results for the three and nine months ended September 30, 2021, which are also available on SEDAR.

Zosano Pharma Corporation, a clinical-stage biopharmaceutical company, announced that the Board of Directors granted a stock option to purchase 220,000 shares of Zosano’s common stock to a new employee as an inducement award.

Hyperfine, Inc., creator of the first FDA-cleared portable magnetic resonance imaging (MRI) device, Swoop®, today announced the FDA 510(k) clearance and launch of its new advanced image reconstruction technology using deep learning (DL).

Alcresta Therapeutics, Inc. announced the appointment of Chris Parrish as its Chief Operations Officer (COO) effective November 29, 2021.

ENDRA Life Sciences Inc. announce today the signing of a collaboration agreement to incorporate ENDRA’s proprietary TAEUS technology to support patient screening and biomarker measurement during VGI’s upcoming Phase 2 study of IVB001,

EQRx to Present at the 4th Annual Evercore ISI HealthCONx Conference.

Modular Medical, Inc. today announced the expansion of its Board of Directors with the appointment of two independent directors, Steven G. Felsher and Philip B. Sheibley.

SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it will host a hospital pipeline update for its novel antifungal, ibrexafungerp, during a webcast on Monday, December 6, at 10 a.m. ET.